
FDA Grants Interchangeable Designation to Adalimumab Biosimilar CT-P17 (Yuflyma)
An announcement has been released that the US Food and Drug Administration (FDA) granted interchangeable biosimilar status to CT-P17 (Yuflyma), also known as adalimumab-aaty, which was designed as a high-concentration (100 mg/mL), citrate-free …